The potential role of immunosuppression, plasmapheresis, and desensitization as treatment modalities for Rh immunization.
D000818:Animals; D000963:Antimetabolites / Q000627:therapeutic use; D001787:Blood Group Incompatibility / Q000188:drug therapy / Q000628:therapy*; D003888:Desensitization, Immunologic; D004899:Erythroblastosis, Fetal / Q000188:drug therapy / Q000628:therapy*; D005260:Female; D005938:Glucocorticoids / Q000627:therapeutic use; D006801:Humans; D007166:Immunosuppressive Agents / Q000627:therapeutic use*; D008253:Macaca mulatta; D008431:Maternal-Fetal Exchange / Q000187:drug effects; D010956:Plasmapheresis; D011247:Pregnancy; D011398:Promethazine / Q000627:therapeutic use*; D012204:Rh-Hr Blood-Group System / Q000276:immunology*
D000963:Antimetabolites; D005938:Glucocorticoids; D007166:Immunosuppressive Agents; D012204:Rh-Hr Blood-Group System; D011398:Promethazine